(RTTNews) - Shares of Y-mAbs Therapeutics, Inc. (YMAB) are up over 100% at $8.53, on news of the company getting acquired by SERB Pharmaceuticals for approximately $412 million.
Under the terms of the merger agreement, SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock for $8.60 per share. The offer price represents a premium of approximately 105% to Y-mAbs' closing share price on August 4, 2025, the last full trading day before the transaction announcement.
Y-mAbs' lead asset is DANYELZA, the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma - a rare and aggressive pediatric cancer.
Upon closing of the tender offer, Y-mAbs will be merged with a subsidiary of SERB, and Y-mAbs' stock will no longer be listed on the Nasdaq exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
